Results 101 to 110 of about 348 (143)

Stepwise Incremental Dose Schedule of Sirolimus Is Successfully Tolerated by a Patient With Lymphangioleiomyomatosis Who Was Initially Allergic to mTOR Inhibitors. [PDF]

Cureus
Seyama K, Komiyama E, Tsuchihashi H, Okura MK, Sekimoto Y, Mitsuishi Y.   +5 more
europepmc   +1 more source

Comparison of Total Hemispherical Reflectance and Emittance Values Between Metformin Extended-Release Tablets Stored Under Ambient and Stress Conditions. [PDF]

Sensors (Basel)
Sarecka-Hujar B, Meisner M.
europepmc   +1 more source

Nasal Mucosal Manifestation of Behçet's Disease. [PDF]

Intern Med
Akiyama H, Otsuka Y, Masuda Y, Soejima Y, Nakamoto K, Katayama Y, Sato A, Hagiya H, Otsuka F.   +8 more
europepmc   +1 more source

Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study. [PDF]

Support Care Cancer
Negoro Y, Maeda T, Igarashi H, Shigemori M, Tanaka T, Ito Y, Tanizawa N, Nishikawa S, Ogawa J, Kamitani Y, Watanabe K, Tsukamoto H, Goto N.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bepotastine besilate for the treatment of perennial allergic rhinitis

Expert Opinion on Pharmacotherapy, 2018
Bepotastine besilate (BB) is a second-generation H1-antihistamine that, as an ophthalmic solution, is approved in the United States by the Food and Drug Administration (FDA) for the treatment of allergic conjunctivitis. In other countries, the oral presentation of BB is widely used for the improvement of symptoms of allergic rhinitis (AR) as well as ...
Ismael Carrillo-Martin, Alexei Gonzalez‐Estrada   +1 more
exaly   +3 more sources

Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate

Current Medical Research and Opinion, 2010
The purpose of this review is to examine published non-clinical literature on the antihistamine bepotastine besilate, including pharmacokinetic and pharmacologic properties.Standard literature searches using diverse databases were used to find articles on bepotastine besilate published between 1997 and 2009.
Jon I, Williams, James A, Gow, Sharon M, Klier, Shannon L, McCue, Anne Marie F, Salapatek, Timothy R, McNamara   +5 more
exaly   +3 more sources

Improved Synthesis of Bepotastine Besilate

Organic Preparations and Procedures International, 2021
Bepotastine besilate (1, Figure 1, synonymous with bepotastine besylate), is a non-sedative highly selective histamine receptor antagonist, which has a stabilizing effect on mast cells.
C. Q. Han, Y. Y. Xia, Q. Sun, Q. G. Zou
openaire   +1 more source

Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy Subjects

Clinical Drug Investigation, 2013
Bepotastine is a second-generation histamine H(1) receptor antagonist that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease. The aim of the present study was to compare the pharmacokinetics of two different bepotastine formulations [bepotastine besilate 10 mg (reference) and bepotastine salicylate 9.64 mg (test)],
Kyoung-Ah, Kim, Ji-Young, Park
openaire   +2 more sources